Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and carfilzomib

imatinib mesylate has been researched along with carfilzomib in 2 studies

Compound Research Comparison

Studies
(imatinib mesylate)		Trials
(imatinib mesylate)		Recent Studies (post-2010)
(imatinib mesylate)		Studies
(carfilzomib)		Trials
(carfilzomib)		Recent Studies (post-2010) (carfilzomib)
11,4779605,773748121716

Protein Interaction Comparison

ProteinTaxonomyimatinib mesylate (IC50)carfilzomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.0608
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)0.0086
Proteasome subunit alpha type-7Homo sapiens (human)0.0608
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)0.0086
26S proteasome regulatory subunit 6AHomo sapiens (human)0.0086
Proteasome subunit beta type-1Homo sapiens (human)0.5937
Proteasome subunit alpha type-1Homo sapiens (human)0.0608
Proteasome subunit alpha type-2Homo sapiens (human)0.0608
Proteasome subunit alpha type-3Homo sapiens (human)0.0608
Proteasome subunit alpha type-4Homo sapiens (human)0.0608
Proteasome subunit beta type-8Homo sapiens (human)0.0407
Proteasome subunit beta type-9Homo sapiens (human)0.7166
Proteasome subunit alpha type-5Homo sapiens (human)0.0608
Proteasome subunit beta type-4Homo sapiens (human)0.0608
Proteasome subunit beta type-6Homo sapiens (human)0.199
Proteasome subunit beta type-5Homo sapiens (human)0.0237
26S proteasome regulatory subunit 7Homo sapiens (human)0.0086
Proteasome subunit beta type-10Homo sapiens (human)0.1339
26S proteasome regulatory subunit 6BHomo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)0.0086
Proteasome subunit beta type-3Homo sapiens (human)0.0608
Proteasome subunit beta type-2Homo sapiens (human)0.7493
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)0.0086
26S proteasome complex subunit SEM1Homo sapiens (human)0.0086
Proteasome subunit alpha type-6Homo sapiens (human)0.0608
26S proteasome regulatory subunit 4Homo sapiens (human)0.0086
26S proteasome regulatory subunit 8Homo sapiens (human)0.0086
26S proteasome regulatory subunit 10BHomo sapiens (human)0.0086
Glutathione S-transferase omega-1Homo sapiens (human)0.15
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)0.0086
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)0.0086
Proteasome subunit alpha-type 8Homo sapiens (human)0.0608
Proteasome subunit beta type-7Homo sapiens (human)0.0578
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)0.0086

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A1
Tazi, I1

Other Studies

2 other study(ies) available for imatinib mesylate and carfilzomib

ArticleYear
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
    Scientific reports, 2020, 03-20, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays

2020
[Antineoplasic drug repurposing in hematology for COVID-19 treatment].
    Bulletin du cancer, 2021, Volume: 108, Issue:4

    Topics: Adenine; Aniline Compounds; COVID-19 Drug Treatment; Drug Repositioning; Hematologic Neoplasms; Humans; Imatinib Mesylate; Janus Kinases; Nitriles; Oligopeptides; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinolines

2021